Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known a… Read more
Cassava Sciences Inc (SAVA) - Total Liabilities
Latest total liabilities as of September 2025: $48.16 Million USD
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has total liabilities worth $48.16 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cassava Sciences Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Cassava Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cassava Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Cassava Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNIMECH
NSE:UNIMECH
|
India | ₹1.64 Billion |
|
Xpro India Limited
NSE:XPROINDIA
|
India | ₹-6.10 Billion |
|
Knowmerce
KQ:473980
|
Korea | ₩14.26 Billion |
|
Manitex International Inc
NASDAQ:MNTX
|
USA | $164.62 Million |
|
Univacco Technology
TWO:3303
|
Taiwan | NT$1.69 Billion |
|
EVA Precision Industrial Holdings Limited
F:GZT
|
Germany | €4.29 Billion |
|
KlaraBo Sverige AB Series B
ST:KLARA-B
|
Sweden | Skr5.87 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Cassava Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cassava Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cassava Sciences Inc (1999–2024)
The table below shows the annual total liabilities of Cassava Sciences Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -43.30% |
| 2021-12-31 | $12.87 Million | +512.71% |
| 2020-12-31 | $2.10 Million | +51.41% |
| 2019-12-31 | $1.39 Million | +171.43% |
| 2018-12-31 | $511.00K | -54.86% |
| 2017-12-31 | $1.13 Million | +70.23% |
| 2016-12-31 | $665.00K | -73.93% |
| 2015-12-31 | $2.55 Million | +200.12% |
| 2014-12-31 | $850.00K | -52.80% |
| 2013-12-31 | $1.80 Million | -95.88% |
| 2012-12-31 | $43.72 Million | -19.88% |
| 2011-12-31 | $54.57 Million | -17.65% |
| 2010-12-31 | $66.26 Million | -10.16% |
| 2009-12-31 | $73.75 Million | -17.27% |
| 2008-12-31 | $89.15 Million | -14.04% |
| 2007-12-31 | $103.71 Million | -20.55% |
| 2006-12-31 | $130.54 Million | -14.36% |
| 2005-12-31 | $152.44 Million | +1855.30% |
| 2004-12-31 | $7.80 Million | +97.32% |
| 2003-12-31 | $3.95 Million | +27.41% |
| 2002-12-31 | $3.10 Million | +23.08% |
| 2001-12-31 | $2.52 Million | +2.74% |
| 2000-12-31 | $2.45 Million | +715.86% |
| 1999-12-31 | $300.59K | -- |